ClinicalTrials.gg
TerminatedNCT00255034Updated Apr 6, 2017Results posted

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

A Phase 4 interventional study of Peginterferon alfa-2b and Peginterferon alfa-2b in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Why this study was terminated
Recruitment targets were unachievable in the currently available population.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
13th of 39
146 · median 99
Started
2005
with 7 others
Phase 4
10 of 40
none open now
Registered
7th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2005, is one of 10 in phase 4, and was the 7th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

This is an Australian, open-label, multicenter, randomized, double-blind clinical trial designed to assess the efficacy of combination therapy with pegylated interferon alfa-2b and ribavirin for 48 weeks versus 24 weeks in the treatment of chronic hepatitis C (treatment-naïve genotype 3 subjects with high viral loads who have a METAVIR score of at least F1A2). The primary endpoint will be a sustained virological response defined by undetectable HCV RNA in serum at 24 weeks after completion of therapy.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

Keywords

  • chronic hepatitis C
  • pegylated interferon alfa-2b
  • ribavirin
  • Australia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Comply with all current Australian Schedule of Pharmaceutical Benefits S100 eligibility criteria.
  • Chronic genotype 3 infection with a viral load of at least 2 million copies per mL.
  • Able to give written .
  • Understand and be able to adhere to the dosing and visit schedules.
  • Compensated liver disease with the following minimum hematologic and biochemical criteria:

    • ≥120 g/L (females), ≥130 g/L (males)
    • ≥100 x 10\^9/L
    • ≥1.5 x 10\^9/L
    • >50 mL/minute
    • Thyroid stimulating hormone (TSH) within normal limits
  • Serum surface antigen (HBsAg) and (HIV) negative.
  • Negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • Suspected to interferon, pegylated interferon alfa-2b, or ribavirin.
  • Participation in any other drug program within 30 days of the screening visit for this protocol.
  • Any cause of liver disease based on patient history and other than chronic , including but not limited to: hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, hepatitis, alcoholic liver disease, drug-related liver disease.
  • Hepatocellular carcinoma.
  • Decompensated cirrhosis (ascites, history of encephalopathy or bleeding varices, serum albumin \<35 g/L, (PT) prolonged by greater than 3 sec).
  • Significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, myocardial infarction, severe hypertension, or significant arrhythmia) or participants with an showing abnormalities.
  • Immunologically-mediated disease, (e.g. inflammatory bowel disease), idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis).
  • Hemophilia or any hemoglobinopathy, including but not limited to thalassemia major.
  • Severe psychiatric condition, including major depression, a history of major psychoses, current suicidal ideation, and/or suicidal attempts.
  • Ongoing substance abuse, e.g. alcohol, I.V. drugs or inhalants that in the opinion of the investigator would jeopardize the patient's ability to comply with study requirements.
  • Clinically significant ophthalmological disorders.
  • Treatment or recent treatment with agents (excluding short-term withdrawal) and immunosuppressed transplant recipients.
  • Poorly controlled thyroid disease.
  • Any other condition that in the opinion of the investigator would make the patient unsuitable for enrolment, or could interfere with the patient participating in and completing the clinical trial program.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Active comparator
    24 weeks of therapy

    Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 24 weeks

    Biological: Peginterferon alfa-2b · Drug: Ribavirin

  • Experimental
    48 weeks of therapy

    Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 48 weeks

    Biological: Peginterferon alfa-2b · Drug: Ribavirin

Interventions

  • Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks

    Also known as: SCH 54031, PegIntron

  • Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks

    Also known as: SCH 54031 PegIntron

  • 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks

    Also known as: SCH 18908 Rebetol

  • 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks

    Also known as: SCH 18908 Rebetol

06

What researchers measure

Primary outcomes

  1. Sustained Virological Response (SVR), Defined by Undetectable HCV RNA in Serum at 24 Weeks After Completion of Therapy

    No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfill the recruitment target.

    Time frame: 24 weeks after completion of either up to 24 or 48 weeks of therapy

07

Results

Posted Jul 23, 2009
Limitations and caveats
No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfill the recruitment target.

Participant flow

The target recruitment was not attained within the anticipated study time-frame and so study recruitment was ceased on 24 November 2006; however those patients already enrolled in the study continued in the study until completion.

Participant flow — Overall Study
Milestone24 Weeks of Therapy48 Weeks of Therapy
Started7964
Completed6426
Not completed1538
Withdrew: Withdrawal by subject1538

Outcome measures

PrimarySustained Virological Response (SVR), Defined by Undetectable HCV RNA in Serum at 24 Weeks After Completion of Therapy

No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfill the recruitment target.

Time frame:
24 weeks after completion of either up to 24 or 48 weeks of therapy
Reported as:
Number · Participants
Sustained Virological Response (SVR), Defined by Undetectable HCV RNA in Serum at 24 Weeks After Completion of Therapy
Participants24 Weeks of Therapy48 Weeks of Therapy
Sustained Virological Response (SVR), Defined by Undetectable HCV RNA in Serum at 24 Weeks After Completion of Therapy5536

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
24 Weeks of Therapy—8/79 (10.1%)79/79 (100%)
48 Weeks of Therapy—9/64 (14.1%)64/64 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
Event24 Weeks of Therapy48 Weeks of Therapy
CELLULITISInfections and infestations2/790/64
DEPRESSIONPsychiatric disorders2/790/64
NEUTROPENIABlood and lymphatic system disorders0/791/64
THYROIDITISEndocrine disorders0/791/64
ABDOMINAL PAINGastrointestinal disorders0/791/64
ASCITESGastrointestinal disorders0/791/64
INGUINAL HERNIAGastrointestinal disorders0/791/64
BUDD-CHIARI SYNDROMEHepatobiliary disorders0/791/64
ANKLE FRACTUREInjury, poisoning and procedural complications0/791/64
NECK INJURYInjury, poisoning and procedural complications0/791/64
Most frequent other events
Showing 10 of 59
Most frequent other events
Event24 Weeks of Therapy48 Weeks of Therapy
INFLUENZA LIKE ILLNESSGeneral disorders40/7941/64
HEADACHENervous system disorders40/7934/64
FATIGUEGeneral disorders38/7930/64
NAUSEAGastrointestinal disorders28/7925/64
INSOMNIAPsychiatric disorders30/7919/64
IRRITABILITYGeneral disorders20/7920/64
MYALGIAMusculoskeletal and connective tissue disorders24/7912/64
DECREASED APPETITEMetabolism and nutrition disorders22/7914/64
LETHARGYNervous system disorders18/7917/64
DEPRESSIONPsychiatric disorders20/7917/64

Baseline characteristics

Age, Continuous
Age, Continuous(years)24 Weeks of Therapy48 Weeks of TherapyTotal
Mean40.9 ± 9.2040.5 ± 9.8040.7 ± 9.44
Sex/Gender, Customized
Sex/Gender, Customized(participants)24 Weeks of Therapy48 Weeks of TherapyTotal
Female271239
Male5251103
Transgender011
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2005
First posted
Nov 17, 2005
Start
Feb 2005
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Jul 23, 2009
Last update
Apr 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00255034
Responsible party
Sponsor
First posted
Nov 17, 2005
Start date
Feb 2005
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Jul 23, 2009
Last update
Apr 6, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion